Pacific Biosciences of California
Open
$1.32
Prev. Close
$1.31
High
$1.32
Low
$1.31
Market Snapshot
$395.62M
-3.1
-1.13
$154.01M
485
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. The company focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. The company focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.
Recently from Cashu
Pacific Biosciences: Leading the Genomic Revolution in Healthcare Investment Shifts
Genomic Technologies: A Catalyst for Transformation in Healthcare and Beyond Cathie Wood, CEO of ARK Invest, emphasizes a transformative shift in investment strategy focused on genomic technologies, s…
It seems you haven't provided the content to summarize. Please share the text, and I'll be happy to help!
Please provide the text you would like me to summarize.
Pacific Biosciences of California Enhances Genomic Sequencing Amid Positive Market Trends
Pacific Biosciences Strengthens Position in Genomic Sequencing Amid Market Optimism Pacific Biosciences of California, a leader in the field of genomic sequencing, continues to enhance its technologic…
Pacific Biosciences of California: Pioneering Innovations in Genomic Sequencing Technology
Pacific Biosciences: Advancements in Genomic Sequencing Technology Pacific Biosciences of California continues to lead the charge in revolutionizing genomic sequencing technology with its innovative p…